Cervical Esophageal Cancers: Challenges and Opportunities
- 64 Downloads
Purpose of the Review
Cervical esophageal cancers (CECs) are a rare subset of esophageal cancers that are distinct in their management and outcomes. This review explores current data on the optimal management of this disease.
While outcomes for CEC have been suboptimal, several strategies have been proven beneficial in recent years. These include selective surgical resection or salvage surgery, chemoradiation (CRT) vs. radiation (RT) alone, dose escalation, IMRT, and induction chemotherapy.
The optimal management of CEC to achieve the best oncological outcomes and minimize morbidity appears to be definitive chemoradiation with surgery reserved for selective salvage. While the benefit of dose escalated vs. standard dosing for radiation is unclear, most appear to use doses in excess of 50.4 Gy, even in the United States. IMRT might provide a benefit independent of allowing for dose escalation. Induction chemotherapy might allow for “chemoselection”, but the benefit is unclear.
KeywordsCervical esophagus cancer Proximal esophagus Squamous cell carcinoma Radiation dose escalation Chemoradiation IMRT
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Amin MB. AJCC Cancer staging system, 8th edition. Am Jt Commitee Cancer. 2017Google Scholar
- 4.van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MI van B, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012Google Scholar
- 5.Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018Google Scholar
- 8.NCCN. NCCN Clinical practice guidelines in oncology (NCCN guidelines) - esophageal and esophagogastric junction cancers. JNCCN J Natl Compr Cancer Netw. 2017Google Scholar
- 9.Takebayashi K, Tsubosa Y, Matsuda S, Kawamorita K, Niihara M, Tsushima T, et al. Comparison of curative surgery and definitive chemoradiotherapy as initial treatment for patients with cervical esophageal cancer. Dis Esophagus. 2017Google Scholar
- 11.• Cao CN, Luo JW, Gao L, Xu GZ, Yi JL, Huang XD, et al. Primary radiotherapy compared with primary surgery in cervical esophageal cancer. JAMA Otolaryngol - Head Neck Surg. 2014. A large series of surgical and non-surgical patients are also looking at the benefit of adjuvant therapy. Google Scholar
- 19.Li HX, Liu J, Cheng Y, Liu MN, Fang WT, Lv CX. Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study. Dis esophagus Off J Int Soc Dis Esophagus. 2018Google Scholar
- 20.•• Zenda S, Kojima T, Kato K, Izumi S, Ozawa T, Kiyota N, et al. Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Radiat Oncol Biol Phys. 2016. The only prospective series dedicated to chemoradiation for cervical esophageal cancers with clear data on outcomes and toxicity. Google Scholar
- 22.• McDowell LJ, Huang SH, Xu W, Che J, Wong RKS, Brierley J, et al. Effect of intensity modulated radiation therapy with concurrent chemotherapy on survival for patients with cervical esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2017. A well-done series looking at the potential benefit of IMRT over other radiation techniques. Google Scholar
- 23.Ito M, Kodaira T, Tachibana H, Tomita N, Makita C, Koide Y, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head Neck. 2017;39:2406–15.CrossRefGoogle Scholar
- 26.Ludmir EB, Palta M, Zhang X, Wu Y, Willett CG, Czito BG. Incidence and prognostic impact of high-risk HPV tumor infection in cervical esophageal carcinoma. J Gastrointest Oncol. 2014Google Scholar
- 27.• De B, Rhome R, Doucette J, Buckstein M. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base (NCDB) analysis. Dis esophagus Off J Int Soc Dis Esophagus. 2017;30. A very large series on cervical esophageal cancer looking at the effects of dose escalation on overall survival. Google Scholar
- 28.Stuschke M, Stahl M, Wilke H, Walz M, Oldenburg A, Stüben G, et al. Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus. Am J Clin Oncol Cancer Clin Trials. 2000;23:233–8.CrossRefGoogle Scholar
- 31.Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol [Internet]. Elsevier; 2013 [cited 2019 Mar 8];14:257–64. Available from: https://www.sciencedirect.com/science/article/pii/S1470204513700111?via%3Dihub. Accessed February 25, 2019.
- 32.Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. American Society of Clinical Oncology. 2014;32:2735–43. https://doi.org/10.1200/JCO.2013.54.6309.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Chen Z, Ren Y, Du XL, Yang J, Shen Y, Li S, et al. Incidence and survival differences in esophageal cancer among ethnic groups in the United States. Oncotarget. 2017Google Scholar